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Abstract
Concurrent chemotherapy and radiotherapy (cCRT) is considered the standard treatment of
locally advanced non-small cell lung cancer (LA-NSCLC). Unfortunately, management is
still heterogeneous across different specialists. A multidisciplinary approach is needed in
this setting due to recent, promising results obtained by consolidative immunotherapy. The
aim of this survey is to assess current LA-NSCLC management in Italy. From January to
April 2018, a 15-question survey focusing on diagnostic/therapeutic LA-NSCLC manage-
ment was sent to 1,478 e-mail addresses that belonged to pneumologists, thoracic sur-
geons, and radiation and medical oncologists. 421 answers were analyzed: 176 radiation
oncologists, 86 medical oncologists, 92 pneumologists, 64 thoracic surgeons and 3 other
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specialists. More than a half of the respondents had been practicing for >10 years after com-
pleting residency training. Some discrepancies were observed in clinical LA-NSCLC man-
agement: the lack of a regularly planned multidisciplinary tumor board, the use of upfront
surgery in multistation stage IIIA, and territorial diffusion of cCRT in unresectable LA-
NSCLC. Our analysis demonstrated good compliance with international guidelines in the
diagnostic workup of LA-NSCLC. We observed a relationship between high clinical experi-
ence and good clinical practice. A multidisciplinary approach is mandatory for managing LA-
NSCLC.
Introduction
Concomitant radiotherapy and chemotherapy (cCRT) represents the standard of care in “fit
patients” (defined as patients with good performance status, no or mild comorbidities, and
potentially able to undergo a multimodal approach as reported in the RTOG0617 trial) with a
diagnosis of locally advanced non-small cell lung cancer (LA-NSCLC) [1–2]. This combination
is widely adopted due to strong, evidence-based results on overall survival (OS), progression
free survival (PFS), and local control (LC) [3–4] when compared to a sequential approach.
Despite the introduction of and improvements in image-guided radiotherapy (IGRT) (e.g.
using pre-planned positron emission tomography–PET-CT) and radiation technologies (e.g.
intensity modulated radiotherapy–IMRT), OS is still disappointing and generally unimpacted
by the addition of surgery [5]. In particular, cCRT is characterized by a higher risk of develop-
ing acute and late toxicities (i.e. esophagitis and pneumonitis), and only 40% of LA-NSCLC
patients are candidates for this approach [6]. Particularly, “fit patients” (e.g. perfomance status
0–1, median age< 65 years, Caucasian, few comorbidities) are reported to have interesting
OS, such as in the RTOG0617 trial in which the control group had a median OS of 28.7
months and a 2-year OS of 57.6% [5]. Recently, good results were obtained using immunother-
apy (IT) after cCRT with a significant improvement in PFS and OS, with no impact in severe
acute/late toxicity profiles [5,7–8].
The management of LA-NSCLC seems to be inhomogeneous between oncological centers
and specialists due to the challenges of selecting fit patients, the recent introduction of IT, and
the consequentially differing expertise in LA-NSCLC management. The aim of this survey was
to assess the management of LA-NSCLC in Italy, asking all involved specialists (pneumologists
[PN], thoracic surgeons [TS], radiation [RO] and medical oncologists [MO]) so as to illumi-
nate potentially critical issues, improve good clinical practice, and better understand the differ-
ent approaches between specialists.
Materials and methods
The survey was promoted on behalf of the Italian Radiation Oncologist Association (AIRO), as
well as supported and endorsed by the Italian Pneumologists Association (AIPO) and Italian
Thoracic Surgery Society (SICT). The questionnaire was divided into three sections: inter-
viewer features, diagnostic management, and treatment approach.
An online, web-based survey was developed using a dedicated web platform (http://www.
xsurvey.cloud). The survey was first planned in November 2016 and completed in April 2017.
The questionnaire was written in Italian, and is provided in S1 Appendix.
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Initially, all the written questions were submitted for analysis and approval by the Scientific
Committee of AIRO (composed of national experts in clinical oncology). After initial AIRO
Scientific Committee approval, the questions were then submitted to the AIRO Directory
Board for final approval. Finally, in January of 2018, an initial e-mail with a link to the web-
based questionnaire was sent to all AIRO members involved in thoracic oncology, and conse-
quently to TS and PN dedicated to thoracic malignancy in daily clinical practice. The Medical
Oncologists Society was also asked to forward the survey to physicians who manage lung can-
cer treatments. The survey was strictly confidential and anonymous, and designed to be com-
pleted in approximately 15 minutes. Initial responses were reviewed by AIRO Thoracic
Oncology Group board members. A general reminder was sent one month later to obtain a
greater rate of answers, and survey responses were collected until April 2018.
All responses (including partial responses) were deemed eligible and analyzed through
descriptive statistics. Specifically, two statistical analyses were performed in order to investigate
variability in answer distribution. First, subgroups were created from the total population
based on specialization (PN, TS, radiation [RO] and medical oncologists [MO]), level of expe-
rience, workings hours spent on lung tumors issues, and rate of multidisciplinary case discus-
sion. These subgroups were used to define current, clinical lung cancer practice in Italy by
presenting interviewees with case studies for response. For this analysis, answers were given in
a multi-choice format with no response considered “correct” or “incorrect”.
Second, these subgroups were correlated with a “correct” response rate using the responses
to the same set of case studies. “Correct” answers were defined as adhering to international
guidelines (such as the ESMO) by the core of experts who planned the survey (S2 Appendix).
Each subgroup was compared with the rest of the interviewed population in terms of answer
distribution, indicating statistical significance when p<0.05.
Both the above analyses were conducted using the Pearson chi-square test. As a survey
involving neither therapeutic choice on humans nor demographic data, it did not require any
ethics committee approval.
Results
The survey was sent to 1,478 email-addresses. 421 responses were received (with an overall
response rate of 28%), divided as follows: 176 (42%) RO, 86 (20%) MO, 92 (22%) PN, 64 (15%)
TS and 3 (1%) other specialists. The features of all respondents are summarized in Table 1.
Regarding second level staging in LA-NSCLC, most respondents (63%) declared that a
patient with a new LA-NSCLC diagnosis with mediastinal PET positivity required complete
staging with endobronchial ultrasound-guided/trans-bronchial needle aspiration (EBUS/
TBNA) (Fig 1). Interestingly, being a RO or TS seemed to positively influence the chance of
reporting correct answers, as defined previously (p = 0.001 and p = 0.0001, respectively).
Other characteristics with a statistically positive impact on the rate of correct answers were 10
to 15 years of experience (p = 0.025), the working hours spent on lung tumors (�50%), the
presence of a weekly multidisciplinary team meeting (p = 0.04), and the number of treated
patients (at least 10 per year, p = 0.011). EBUS/TBNA was the diagnostic standard choice for
57% of responders, even in case of lymph nodal mediastinal PET negativity. No other addi-
tional diagnostic tests were necessary for 99 colleagues (24%) (Fig 2).
Of note, almost half of the respondents (43%) considered at least a histological differential
diagnosis between adenocarcinoma and squamous cell carcinoma mandatory before planning
a radical treatment. On the other hand, 22% of lung specialists preferred to proceed with muta-
tional analysis, and only 15% needed PDL-1 expression (question number 11). It is important
to note that this survey was administered before the results of the PACIFIC trial [8].
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Dedicating less than 50% of the total working hours to lungs predisposed one to a higher rate
of wrong answers to this question (p = 0.021).
Questions about therapeutic choices were presented in the form of clinical cases. Neoadju-
vant chemotherapy (CT) followed by surgery was recommended by 43% of specialists (Fig 3)




Radiation Oncology 176 (42%)
Medical Oncology 86 (20%)
Pneumology 92 (22%)





General hospital 23 (6%)
Private 23 (6%)
Years in practice:
0–5 years 128 (31%)
5–10 years 51 (12%)
10–15 years 79 (19%)
> 15 years 158 (38%)





Representative physician in diagnostic and staging process:
Radiation Oncologist 7 (2%)








Rate of multidisciplinary case discussion:
Yes, with weekly meetings 295 (72%)
Yes, with meetings every two weeks 34 (8%)
Yes, but not regularly 41 (10%)
None 41 (10%)
Number of patients with LA-NSCLC treated in the last year:
> 30 pts 30 (34%)
20–30 pts 108 (26%)
10–20 pts 117 (29%)
<10 pts 45 (11%)
https://doi.org/10.1371/journal.pone.0224027.t001
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in a patient with cT1b cN2, single station involvement lung adenocarcinoma (stage IIIA), and
fit for surgery. Instead, in a patient fit for surgery with clinical stage cT2 cN2 and multiple
Fig 1. LA-NSCLC lymph nodal mediastinal PET positivity–question 9.
https://doi.org/10.1371/journal.pone.0224027.g001
Fig 2. LA-NSCLC diagnosis with lymph nodal negativity–question 10.
https://doi.org/10.1371/journal.pone.0224027.g002
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positive lymph node stations (stage IIIA), 32% of respondents declared a preference for radical
cCRT (Fig 4). Even in this case, experience with lung tumors was essential: more than 15 years
of experience and dedicating more than 70% of the total working hours to lung cancer were
positively correlated with a correct answer (p = 0.009 and p = 0.041, respectively). Almost half
of respondents (48%) thought that radical cCRT, if not performed in a neoadjuvant setting,
was the best approach for inoperable lung adenocarcinoma in partial response/stability (ycN2)
after neoadjuvant chemotherapy. Surgery (only with a feasible lobectomy) and radiotherapy
(RT) alone (if not administered in a neoadjuvant setting) were the best treatment options for
23% and 19% of lung specialists, respectively. The remaining part voted for CT alone or sur-
gery, independently from the applied technique (Fig 5).
54% of respondents declared that upfront cCRT should be the preferred treatment for stage
IIIA-B NSCLC patients; cCRT followed by consolidation CT was the best choice for 33%.
Moreover, sequential CTRT was a reasonable treatment option for the remaining 13% of the
interviewees (question number 15). For most respondents, acute toxicity and logistical barriers
were reasonable contraindications for a concomitant approach in a patient fit for surgery with
stage IIIA-B NSCLC or cCRT in stage IIIA-B (question number 16).
Fig 3. LA-NSCLC clinical stage cT1b cN2, single station, fit for surgery—question number 12.
https://doi.org/10.1371/journal.pone.0224027.g003
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After the first analysis, a significant difference was observed between the average response
of the entire population and the various subgroups for each question analyzed both in diagno-
sis management and in therapeutic management (S3 Appendix and S4 Appendix).
Fig 4. LA-NSCLC clinical stage cT2cN2, multiple stations, IIIB—question number 13.
https://doi.org/10.1371/journal.pone.0224027.g004
Fig 5. LA-NSCLC inoperable in partial response/stability (ycN2) after neoadjuvant chemotherapy—question number
14.
https://doi.org/10.1371/journal.pone.0224027.g005
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The results of the second statistical analysis comparing subgroups according to correct
answers are shown in S5 Appendix and S6 Appendix. The p-value indicates whether a signifi-
cant difference exists between each subgroup and the total population, and the percentage
reflects the correct answer rate.
Discussion
To the best of our knowledge, this is the first multidisciplinary survey in Europe that collected
data about the management of Stage III NSCLC. Focusing on diagnostic approaches, we
observed global agreement on the management of second level staging in mediastinal histo-
pathological proof in accordance with ESMO (European Society of Medical Oncology) and
ESTS (European Society of Thoracic Surgeons) clinical guidelines [9]. In particular, EBUS
with FNA (fine-needle aspiration) was preferred over video-assisted mediastinoscopy (VAM)
because it is minimally invasive and has acceptable sensitivity (83% and 94%) [10–11].
In our survey, over 70% of physicians agreed with an invasive histopathological proof in
suspect mediastinal lymph nodes, and EBUS was considered the main invasive staging
approach. The answers were conditioned by the availability of procedural equipment or
resources.
Regarding histopathological and molecular analysis, nearly half of the physicians (43%)
considered a diagnosis of adenocarcinoma or squamous cell carcinoma acceptable for a locore-
gional oncological approach. Surprisingly, 22% recommended a molecular analysis (EGFR,
ROS, ALK1 status) in unresectable LA-NSCLC, in which platinum-based chemotherapy and
radiotherapy represent the standard of care [12].
The PACIFIC trial demonstrated that durvalumab improved progression-free survival (HR
0.52; 95% CI, 0.42 to 0.65; P<0.001) [7] and overall survival (HR, 0.68; 99.73% CI, 0.47 to
0.997; p = 0.0025) [8] compared to placebo. This approach has since modified clinical manage-
ment (excluding patients with a PD-L1 level< 1%), and the evaluation of PD-L1 status would
be systematically requested in this setting. These findings could justify the answer given by
15% of survey responders, according to EMA approval.
Regarding diagnostic management, we observed some heterogeneity in the subgroup analy-
sis, as reported in S3 and S4 Appendices. In particular, there was a close correlation between
high expertise, over>50% of working hours being dedicated to the management of
LA-NSCLC, weekly multidisciplinary discussions, and good clinical practice.
The clinical guidelines recognize the importance of multidisciplinary meetings (MDM) in
the management of lung cancer patients, as an early diagnosis can significantly impact survival,
while the most appropriate treatments must be selected based on the clinical condition of the
lung cancer patient [13, 14], especially in stage III NSCLC [15].
In general terms, dedicated lung cancer MDMs should feature the participation of key pro-
fessionals: radiation oncologists, medical oncologists, thoracic surgeons, pneumologists, radi-
ologists, nuclear medicine physicians, pathologists, and specialist nurses.
Another finding from this survey was the clinical management of different, locally
advanced NSCLC disease, including potentially resectable and unresectable cases. In our sur-
vey, in cT1bN2 (Stage IIIA—single station), 43% of physicians proposed neoadjuvant CT fol-
lowed by resection, while for 23%, upfront surgical resection was considered appropriate.
These results underline that lobectomy and lymph node dissection are considered feasible in
single N2 lymph node and limited T-stage cancer.
Certainly, surgery is accepted by the international community as the cornerstone approach
in the management of lung cancer. In the ESMO guidelines [11], for patients with single N2
station involvement and early stage primary NSCLC, a lung resection followed by adjuvant
Survey on multimodal management of locally advanced non small cell lung cancer
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systemic therapy or neoadjuvant CT and surgery are both considered acceptable, even though
it remains an open issue.
Regarding the correct approach for a patient with unresectable stage III NSCLC who had
been treated with neoadjuvant CT and persistent N2 (ycN2), almost half of physicians (48%)
considered cCRT the standard of care.
Finally, for cT2N2 (Stage IIIA—multiple stations, no bulky disease), there was diversity
among the answers: 32% of physicians supported a radical cCRT treatment, 27% considered
neoadjuvant CT as a feasible strategy, and 23% proposed surgery after CT or cCRT.
In both scenarios, cCRT (Level IA) is the most appropriate therapeutic approach according
to ESMO guidelines. However, in centers with an experienced multidisciplinary team, a multi-
modality approach including surgery can be considered in select cases (Level of Evidence IV
C) [12].
Nevertheless, surgical resection could be considered even if different clinical experiences do
not significantly impact clinical outcomes after a trimodality approach. In the Lung Intergroup
0139 trial, the induction of CT and RT followed by surgery did not prove advantageous for OS
when compared to radical cCRT due to higher pneumonectomy-related toxicities. [16]. More
recently, two additional studies explored the use of a neoadjuvant CTRT combination, but
without a clear benefit for clinical outcomes [17, 18]. For these reasons, trimodality therapy
cannot be considered the standard of care in locally advanced NSCLC.
When a locally advanced NSCLC patient was not considered eligible for surgery, upfront
cCRT was considered the standard of care by 54% of physicians. This clinical approach agrees
with the principal international guidelines and meta-analysis, confirming the advantage of
cCRT compared to sequential RT [1, 12].
Despite the consideration of acute toxicity as the primary impetus for avoiding cCRT treat-
ments, we still observed that in 8% of physicians, prescribing sequential C-RT was correlated
to logistical limitations. Also, in the management of clinical cases, we observed a relationship
between large clinical experience and good clinical practice, underlying the role of a multidis-
ciplinary approach and expertise in LA-NSCLC management.
The results from the PACIFIC trial will modify daily clinical practice, and it is critical to
improve education and multidisciplinary approaches in the management of LA-NSCLC to
define the most appropriate diagnostic and therapeutic management strategy.
Study limitations, strengths, and future perspectives
During the planning stage of the present survey, a discussion was held among the members of
the AIRO Thoracic Oncology Group to clarify the main research goals. The promoters were
aware of the reservations regarding surveys, which are generally a poor method for collecting
data and opinions on current clinical practice. We could not verify the self-reported data, and
respondents’ memories are often unreliable. Moreover, we could not quantify practice out-
comes, but we did obtain data on expert opinions, beliefs, and ideas regarding LA-NSCLC
management in Italy. We now have a sense of the extent of agreement and disagreement
among the various specialists regarding LA-NSCLC approaches. Such information could serve
as the proof of principle for a consensus conference, designed to establish multidisciplinary
indications for the staging and treatment of pulmonary LA-NSCLC. Moreover, this informa-
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S2 Appendix. Correct answers accepted by NSCLC experts.
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S3 Appendix. Statistical analysis for diagnostic management comparing subgroups and
entire population [table].
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S4 Appendix. Statistical analysis for therapeutic management comparing subgroups and
entire population [table].
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S5 Appendix. Statistical analysis for diagnostic management comparing subgroups and
correct answers [table].
(DOCX)
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